In addition, the downregulation of NEAT1 also repressed NLRP3 inflammasome activation through miR-1301-3p/gap junction protein beta 1 (GJB1) signaling pathway regulation, making it a possible target for PD treatment [196]. The gene discussed is NLRP3; the disease is Parkinson disease.